Astrazeneca Ab

Neomed Institute

Heptares Therapeutics Limited

Epigenetix, Inc.

Medimmune Limited

Shawn Donald Johnstone

Andrew Griffin

Malken Bayrakdarian

Jeffrey S Albert

Stephen Claridge

Guillaume Jacquemot

Denis Labrecque

Mehrnaz Pourashraf

Miles Stuart Congreve

Giles Albert Brown

Benjamin Gerald Tehan

William Brown

Barry John Teobald

Karl Henrik Edman

Yevgeni Besidski

Inger Kers

Paul Jones

Karin Skogholm

Dean Gordon Brown

Roland Werner Burli

John Graham Cumming

Frank Xinhe Wu

Hongming Chen

Martin Nylöf

Martin Nylof

Roland Bürli

Stephane Turcotte

Marc-Andre Beaulieu

Johan Bartholomeus

Rebecca Jarvis

Thor Ostenfeld

Ina Terstiege

Massimiliano Travagli

This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.

Substituted benzimidazoles, their preparation and their use as pharmaceuticals

The present application relates to compounds of formula (I') or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).

Small molecule modulators of the BTB domain of Keap1

The present application relates to certain substituted imidazole compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating pain, musculoskeletal inflammation, neuroinflammatory disorders, airway inflammation, itch, dermatitis, colitis and related conditions.

Inhibitors of protease-activated receptor-2

This application relates to N-substituted bicyclic lactams of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to the N-substituted bicyclic lactams of formula (I) and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers. 

N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals

The present application relates to certain substituted imidazole and triazole compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating pain, musculoskeletal inflammation, neuroinflammatory disorders, airway inflammation, itch, dermatitis, colitis and related conditions. The compounds are of Formula (I) where X is N or CH, Z and Y are N or C (but both not N) and R-Rare as defined herein. 

This application relates to aryl-substituted dihydroquinolinones of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to aryl-substituted dihydroquinolinones and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers. 

Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals

This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines of Formula I and to their use as bromodomain inhibitors.  The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.

Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors

The present invention relates to new compounds or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

Compounds

Provided herein are compounds in accord with Formula I: that are useful in the treatment of pain.

Benzimidazole derivatives

Growing community of inventors

Saint Laurent, Canada

Shawn Donald Johnstone